Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04972903
Other study ID # C20-17
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date August 2021
Est. completion date December 2022

Study information

Verified date July 2021
Source Institut National de la Santé Et de la Recherche Médicale, France
Contact Aurelia Vessière, PhD
Phone +33 (0)5 57 57 15 35
Email aurelia.vessiere@u-bordeaux.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

TB-Speed TB-PK is a cross-sectional PK study of anti-TB treatment nested in the TB-Speed HIV and TB-Speed SAM studies aiming at assessing the impact of malnutrition on PK of rifampicin, isoniazid, pyrazinamide, and ethambutol in TB-HIV co-infected children in Uganda and Zambia.


Description:

Tuberculosis can worsen malnutrition and in turn malnutrition increases the risk of TB. HIV infection is prevalent in children with TB and SAM and is often associated with poor outcomes when present. TB alone is the leading cause of death of among HIV-infected children worldwide accounting for a third of all the death in this group. In 2010, the WHO recommended increased dose for rifampicin (+50%), isoniazid (+100%), and pyrazinamide (+33%) based on PK data showing that plasma drug concentrations in children using standard adult dosages did not reach target levels. In children that are TB/HIV co-infected, drug-drug interactions between anti-TB drugs and antiretroviral drugs are of concern. The investigators hypothesize that HIV-infection and SAM, each one on its own, may have an impact on TB drugs concentrations. Furthermore, SAM is frequent in children with HIV, and may affect the metabolism of anti-TB drugs and consequently result in low serum concentration. TB-Speed TB-PK is a cross-sectional PK study of anti-TB treatment nested in the TB-Speed HIV and TB-Speed SAM studies aiming at assessing the impact of malnutrition on PK of rifampicin, isoniazid, pyrazinamide, and ethambutol in TB-HIV co-infected children. It will be implemented in Uganda and Zambia. Children will also be enrolled from routine care for TB outside of the TB- Speed HIV and TB-Speed SAM studies.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 80
Est. completion date December 2022
Est. primary completion date December 2022
Accepts healthy volunteers No
Gender All
Age group 6 Months to 5 Years
Eligibility INCLUSION CRITERIA: - Gr1. HIV-infected children with SAM - Age 6 months to 5 years - Diagnosed with TB and first line TB treatment to be initiated or started less than 4 weeks prior to inclusion - HIV-infection - SAM as defined by WHO at the time of starting TB treatment - Weight-for-height z-score (WHZ) < -3 SD, - OR MUAC <11.5 cm or - OR presence of bilateral pitting oedema of nutritional origin - Ability to take drugs orally during the planned PK day - Signed informed consent from parents or guardian - Gr2. HIV-infected children without SAM - Age 6 months to 5 years - Diagnosed with TB and first line TB treatment to be initiated or started less than 4 weeks prior to inclusion - HIV-infection - Absence of SAM as defined by WHO at the time of starting TB treatment - Weight-for-height z-score (WHZ) > -3 SD, - AND MUAC >11.5 cm or - AND absence of bilateral pitting oedema of nutritional origin - Ability to take drugs orally during the planned PK day - Signed informed consent from parents or guardian - Gr3. HIV-negative children with SAM - Age 6 months to 5 years - Diagnosed with TB and first line TB treatment to be initiated or started less than 4 weeks prior to inclusion - HIV-negative - SAM as defined by WHO at the time of starting TB treatment - Weight-for-height z-score (WHZ) < -3 SD, - OR MUAC <11.5 cm or - OR presence of bilateral pitting oedema of nutritional origin - Ability to take drugs orally during the planned PK day - Signed informed consent from parents or guardian - Gr4. HIV-negative children without SAM - Age 6 months to 5 years - Diagnosed with TB and first line TB treatment to be initiated or started less than 4 weeks prior to inclusion - HIV-negative - Absence of SAM as defined by WHO at the time of starting TB treatment - Weight-for-height z-score (WHZ) > -3 SD, - AND MUAC >11.5 cm or - AND absence of bilateral pitting oedema of nutritional origin - Ability to take drugs orally during the planned PK day NON INCLUSION CRITERIA: - Very ill or moribund children unable to take drugs orally or requiring nasogastric drug intake - Severe anaemia (Hb < 6 g/dl), - Severe renal impairment (DAIDS grade 3 and above) - Severe hepatic impairment (DAIDS grade 3 and above) - Children on second line TB drugs

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Uganda Mulago National Referral Hospital Kampala
Uganda Mbarara Regional Hospital Mbarara
Zambia The University Teaching Hospital Lusaka
Zambia Arthur Davison Children Hospital Ndola

Sponsors (2)

Lead Sponsor Collaborator
Institut National de la Santé Et de la Recherche Médicale, France National Agency for Research on AIDS and Viral Hepatitis (ANRS)

Countries where clinical trial is conducted

Uganda,  Zambia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Effect of SAM on Peak plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol in children with TB Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol peak concentration (Cmax) 6 months
Primary Effect of SAM on minimum plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol in children with TB Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol minimum concentration (Cmin or C trough) 6 months
Primary Effect of SAM on Area Under the Curve plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol in children with TB Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol exposure (Area Under the Curve - AUC) 6 months
Secondary Effect of HIV-infection and antiretroviral treatment on Peak plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol in children with TB and SAM Cmax of Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol in children with HIV infection on or off ART and children without HIV infection 6 months
Secondary Effect of HIV-infection and antiretroviral treatment on Minimum plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol in children with TB and SAM Cmin of Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol in children with HIV infection on or off ART and children without HIV infection 6 months
Secondary Effect of HIV-infection and antiretroviral treatment on Area Under the Curve plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol in children with TB and SAM AUC of Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol in children with HIV infection on or off ART and children without HIV infection 6 months
Secondary WHO-based dosages will achieve rifampicin, isoniazid, pyrazinamide, and ethambutol drug concentrations above the target therapeutic concentrations in HIV-TB co-infected children with and without SAM Proportion of children with AUC24 and Cmax above the recommended threshold for Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol 6 months
Secondary Effect of personnal parameters (nutritional parameters, HIV-infection, antiretroviral treatment, age, liver enzymes and NAT2 status) on CL/F of rifampicin, isoniazid, pyrazinamide, and ethambutol in HIV-infected children with TB CL/F(Apparent total clearance of the drug from plasma) after oral administration of rifampicin, isoniazid, pyrazinamide, and ethambutol in HIV-infected children with TB. 6 months
Secondary Effect of personnal parameters (nutritional parameters, HIV-infection, antiretroviral treatment, age, liver enzymes and NAT2 status) on V/F of rifampicin, isoniazid, pyrazinamide, and ethambutol in HIV-infected children with TB V/F (Apparent volume of distribution after administration) after oral administration of rifampicin, isoniazid, pyrazinamide, and ethambutol in HIV-infected children with TB. 6 months
Secondary Effect of personnal parameters (nutritional parameters, HIV-infection, antiretroviral treatment, age, liver enzymes and NAT2 status) on Ka of rifampicin, isoniazid, pyrazinamide, and ethambutol in HIV-infected children with TB Ka (Absorption rate constant) after oral administration of rifampicin, isoniazid, pyrazinamide, and ethambutol in HIV-infected children with TB. 6 months
Secondary Relationship between all-cause mortality in children with TB and SAM, and Peak plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol. Define the best Cmax plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol for treatment sucess. 6 months
Secondary Relationship between all-cause mortality in children with TB and SAM, and the minimum plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol. Define the best Cmin plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol for treatment sucess. 6 months
Secondary Relationship between all-cause mortality in children with TB and SAM, and Area Under the Curve plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol. Define the best AUC plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol for treatment sucess. 6 months
Secondary Rifampicin protein binding in relation with malnutrition and albuminemia Proportion of protein bound rifampicin in children with SAM and association with albuminemia 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05738681 - Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial Phase 2/Phase 3
Recruiting NCT05526885 - Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa N/A
Completed NCT04369326 - Community Initiated Preventive Therapy for TB N/A
Recruiting NCT04568967 - TB-CAPT EXULTANT - HIV N/A
Completed NCT02337270 - Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol Phase 1
Not yet recruiting NCT06253715 - Shortened Regimen for Drug-susceptible TB in Children Phase 3
Recruiting NCT04271397 - Immunological Biomarkers in Tuberculosis Management N/A
Withdrawn NCT03639038 - Tuberculosis Diagnosis by Flow Cytometry
Completed NCT03199313 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid Phase 1
Recruiting NCT04975178 - Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa Phase 3
Completed NCT04463680 - Rifampin and the Contraceptive Implant Phase 4
Completed NCT03973970 - Assessing the Ability of the T-SPOT®.TB Test (IQ)
Recruiting NCT04230395 - Alcohol Reduction Among People With TB and HIV in India N/A
Completed NCT04874948 - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment Phase 1
Active, not recruiting NCT02906007 - Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV Phase 1/Phase 2
Not yet recruiting NCT05917210 - Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda N/A
Not yet recruiting NCT05845112 - Start Taking Action For TB Diagnosis
Not yet recruiting NCT06017843 - Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding N/A
Active, not recruiting NCT02715271 - Study of TB Lesions Obtained in Therapeutical Surgery
Completed NCT02781909 - Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis Phase 2